One Wealth Advisors LLC Has $1.33 Million Holdings in Edwards Lifesciences Corporation (NYSE:EW)

One Wealth Advisors LLC boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 54.2% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,304 shares of the medical research company's stock after purchasing an additional 6,431 shares during the quarter. One Wealth Advisors LLC's holdings in Edwards Lifesciences were worth $1,327,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of EW. Vega Investment Solutions bought a new position in Edwards Lifesciences during the 4th quarter worth $27,000. Global X Japan Co. Ltd. grew its stake in Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after buying an additional 216 shares during the last quarter. Tradewinds Capital Management LLC grew its stake in Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after buying an additional 205 shares during the last quarter. Rossby Financial LCC bought a new position in Edwards Lifesciences during the 1st quarter worth $29,000. Finally, ORG Wealth Partners LLC bought a new position in Edwards Lifesciences during the 1st quarter worth $38,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Up 5.4%

Shares of Edwards Lifesciences stock traded up $4.12 on Friday, reaching $79.92. 15,656,685 shares of the company were exchanged, compared to its average volume of 3,810,979. The stock has a fifty day moving average price of $76.58 and a 200-day moving average price of $73.56. The firm has a market capitalization of $46.88 billion, a price-to-earnings ratio of 11.50, a price-to-earnings-growth ratio of 3.81 and a beta of 1.11. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a fifty-two week low of $59.41 and a fifty-two week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.25% and a net margin of 72.96%. Edwards Lifesciences's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.70 earnings per share. On average, analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 2,570 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total transaction of $198,918.00. Following the transaction, the vice president directly owned 50,356 shares of the company's stock, valued at approximately $3,897,554.40. The trade was a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the company's stock in a transaction on Friday, May 9th. The shares were sold at an average price of $74.40, for a total value of $837,000.00. Following the transaction, the chief financial officer directly owned 41,098 shares in the company, valued at $3,057,691.20. The trade was a 21.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,848 shares of company stock valued at $2,314,488 in the last ninety days. Corporate insiders own 1.29% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on EW shares. Citigroup restated a "buy" rating and set a $95.00 price objective (up from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft boosted their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday. Wall Street Zen lowered Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Friday, May 16th. Evercore ISI boosted their price target on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a research report on Friday. Finally, Royal Bank Of Canada boosted their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research report on Friday. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of "Hold" and an average price target of $84.29.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.